By End-Use Vertical

Pharmaceutical and Biotechnology Market Analysis

Cross-industry research covering Pharmaceutical and Biotechnology across 1 market reportspanning ICT / Life Sciences Software.

1 Reports

1 Industries

Reports Covering Pharmaceutical and Biotechnology

Molecular Biology Simulation Software Market to Reach USD 1.8B by 2033 at 9.2% CAGR

ICT / Life Sciences Software·Market: USD 0.87 Billion (2025)·CAGR: 9.2%

The dominant vertical by revenue, driven by in-silico drug discovery, lead optimisation, and ADMET prediction programmes. The GBD 2021 disease burden study's scope of 371 diseases across 204 countries (openalex:W4394894573) underscores the target breadth driving computational chemistry investment. Large pharma groups' increasing multi-year simulation platform commitments are the primary ARR growth driver.

46%

Market Share

9.4%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments